Statistiche di base
| LEI | 5493002O1ESKZ18OXR80 |
| CIK | 1857190 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nyxoah SA
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 18, 2025 |
INTERIM FINANCIAL REPORT FIRST HALF 2025 TABLE OF CONTENTS Table of Contents Exhibit 99.2 INTERIM FINANCIAL REPORT FIRST HALF 2025 TABLE OF CONTENTS Interim financial report 2 1. BUSINESS UPDATE 2 2. FINANCIAL HIGHLIGHTS 4 3. 2025 OUTLOOK 4 4. RISK FACTORS 5 5. FORWARD-LOOKING STATEMENTS 5 Unaudited condensed consolidated interim financial information as at and for the six months ended June 30, 2025 – Interim consolidated statement of financial position 6 |
|
| August 18, 2025 |
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating Results FDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives f |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive of |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive of |
|
| August 11, 2025 |
Exhibit 99.1 Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea U.S. Commercialization Officially Launched Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Ap |
|
| August 11, 2025 |
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Exhibit 99.2 Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial resu |
|
| July 29, 2025 |
Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Exhibit 99.1 Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine July 28, 2025 Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Mont-Saint-Guibert, Belgium – July 28, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough tr |
|
| July 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| June 27, 2025 |
Information on the total number of voting rights and shares Exhibit 99.1 REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 27, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. · Share capital: EUR |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| June 16, 2025 |
Exhibit 99.1 REGULATED INFORMATION June 13, 2025, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “Company”) Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 2, 2025 The board of directors of the Company is pleased to invite its securities holders to attend the ex |
|
| May 30, 2025 |
Publication relating to transparency notifications Exhibit 99.1 REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), May 30, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Vestal Point Capital On May |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 27, 2025 |
Information on the total number of voting rights and shares Exhibit 99.1 Information on the total number of voting rights and shares May 23, 2025 Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), May 23, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information follow |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 14, 2025 |
INTERIM FINANCIAL REPORT FIRST QUARTER 2025 Table of contents Exhibit 99.2 INTERIM FINANCIAL REPORT FIRST QUARTER 2025 Table of contents Table of contents 1 1. Business update 3 2. FINANCIAL HIGHLIGHTS 4 3. 2025 OUTLOOK 5 4. RISK FACTORS 5 5. FORWARD-LOOKING STATEMENTS 6 Unaudited condensed consolidated interim financial information as at and for the three months ended March 31, 2025 – Interim consolidated statement of financial position 7 Unaudited condense |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 14, 2025 |
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports First Quarter Financial and Operating Results Company On Track for Anticipated PMA Approval in the Second Quarter of 2025 Successfully Completed FDA Validation Requirements, Final Site Inspection in Progress Mont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medic |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 9, 2025 |
Exhibit 99.1 NYXOAH SA (Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “Company”) Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 11, 2025 The board of directors of the Company is pleased to invite its securities holders to attend the annual shareholders' meeting of the Company, to be h |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 9, 2025 |
Publication relating to transparency notifications Exhibit 99.1 REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), May 9, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. FMR LLC On May 2, 2025, Nyxoa |
|
| April 16, 2025 |
Conditional Issuance of Shares Exhibit 99.1 INSIDE INFORMATION REGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), today announced a conditional issuance of up to 5 million ordinary shares under its existing at-the-market equity offering programs (the “ATM”). This brings the aggregate |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| April 8, 2025 |
Exhibit 99.1 Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), which develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neur |
|
| March 28, 2025 |
Nyxoah SA Rue Edouard Belin 12 1435 Mont-Saint-Guibert, Belgium Nyxoah SA Rue Edouard Belin 12 1435 Mont-Saint-Guibert, Belgium March 28, 2025 VIA EDGAR U. |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| March 26, 2025 |
FDA Issues Nyxoah an Approvable Letter for its Genio® System Exhibit 99.1 INSIDE INFORMATION REGULATED INFORMATION FDA Issues Nyxoah an Approvable Letter for its Genio® System Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Foo |
|
| March 20, 2025 |
OSA RDI (IEU) Finance Contract between the European Investment Bank Nyxoah SA 3 July 2024 Exhibit 4.14 Certain identified information has been omitted from this exhibit because it is not material and would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been omitted. EIB Internal Classification Corporate Use Contract number (FI No): [***] Serapis No: [***] OSA RDI (IEU) Finance Contract between the European Investment Bank and |
|
| March 20, 2025 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.2 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Nyxoah SA, a Belgian public limited liability company (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December |
|
| March 20, 2025 |
CERTIFICATIONS UNDER SECTION 302 Exhibit 12.1 CERTIFICATIONS UNDER SECTION 302 I, Olivier Taelman, certify that: 1. I have reviewed this annual report on Form 20-F of Nyxoah SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| March 20, 2025 |
Exhibit 1.1 NYXOAH SA Rue Edouard Belin 12 B-1435 Mont-Saint-Guibert Register of legal entities of Walloon Brabant VAT: BE 0817.149.675 CONSOLIDATED VERSION OF THE ARTICLES OF ASSOCIATION AS PER November 15, 2024 TITLE I. Legal form, name, registered office, object and duration Article 1Legal form - Name The company has the legal form of a public limited liability company (naamloze vennootschap/so |
|
| March 20, 2025 |
Ex-107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) NYXOAH SA (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, no nominal value per share (1) 457(h) 805,000 $ 11. |
|
| March 20, 2025 |
CERTIFICATIONS UNDER SECTION 302 Exhibit 12.2 CERTIFICATIONS UNDER SECTION 302 I, John Landry, certify that: 1. I have reviewed this annual report on Form 20-F of Nyxoah SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res |
|
| March 20, 2025 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Nyxoah SA, a Belgian public limited liability company (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December |
|
| March 20, 2025 |
Exhibit 4.15 Certain identified information has been omitted from this exhibit because it is not material and would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been omitted. Corporate Use Execution version FI N° [***] Serapis N° [***] DATED 15 JULY 2024 OSA RDI (IEU) NYXOAH SA as the Company And THE EUROPEAN INVESTMENT BANK as the EIB |
|
| March 20, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No 333-268955) of Nyxoah SA, (2) Registration Statement (Form S-8 No. 333-283103) pertaining to the 2024 Warrants Plan of Nyxoah SA, (3) Registration Statement (Form S-8 No. 333-269410) pertaining to the 20 |
|
| March 20, 2025 |
NYXOAH SA [ ] Trustee Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Exhibit 4.5 NYXOAH SA Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04(a) 5 |
|
| March 20, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
Exhibit 99.1 English translation – for information purposes only NYXOAH SA Rue Edouard Belin 12 B-1435 Mont-Saint-Guibert VAT: BE 0817.149.675 Register of legal entities of Walloon Brabant (hereinafter the "Company") 2025 WARRANTS PLAN 1 DEFINITIONS For the purposes of this Plan, the following terms shall have the following meaning: “Articles of Association” means the articles of association of th |
|
| March 20, 2025 |
Table of Contents As filed with the Securities and Exchange Commission on March 20, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 20, 2025 |
Exhibit 11.1 NYXOAH SA CORPORATE CODE OF CONDUCT AND ETHICS AND WHISTLEBLOWER POLICY Approved by the Board of Directors of Nyxoah SA on 25 June 2021 to be effective as of 2 July 2021 INTRODUCTION Nyxoah SA, a publicly listed limited liability company (“naamloze vennootschap”/”société anonyme”), organized under the laws of Belgium, having its registered office at Rue Edouard Belin 12, 1435 Mont-Sai |
|
| March 20, 2025 |
Ex-107 CALCULATION OF FILING FEE TABLE FORM F-3 (Form Type) NYXOAH SA (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, no nominal value per share (1) 457(o) (1) (1) (1) 0. |
|
| March 20, 2025 |
NYXOAH SA [ ] Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Exhibit 4.4 NYXOAH SA Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act Section of of 1939, as Amended Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04(a) 5.04(b) |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| March 13, 2025 |
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results FDA PMA Application Review Nearing Conclusion Positioned for U.S. Commercial Launch in March 2025 Mont-Saint-Guibert, Belgium – March 13, 2024, 7:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment a |
|
| February 14, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 JOINT FILING 2 p25-0486exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the ne |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive o |
|
| January 2, 2025 |
Publication relating to transparency notifications Exhibit 99.1 REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 20, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On Dece |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| December 13, 2024 |
Exhibit 99.1 Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England December 13, 2024 Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England First patients implanted with Genio at UCLH, London Mont-Saint-Guibert, Belgium – December 13, 2024, 8:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology |
|
| December 2, 2024 |
Information on the total number of voting rights and shares Exhibit 99.1 REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 27, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. · Share capital: |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| November 20, 2024 |
Exhibit 99.1 REGULATED INFORMATION November 19, 2024, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “Company”) Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the |
|
| November 18, 2024 |
Publication relating to transparency notifications Exhibit 99.1 REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), November 18, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On November 15, 2024, N |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| November 8, 2024 |
Exhibit 4.1 English translation, for information purposes only NYXOAH SA Rue Edouard Belin 12 B-1435 Mont-Saint-Guibert Register of legal entities of Walloon Brabant VAT: BE 0817.149.675 CONSOLIDATED VERSION OF THE ARTICLES OF ASSOCIATION AS PER OCTOBER 9, 2024 TITLE I. Legal form, name, registered office, object and duration Article 1 Legal form - Name The company has the legal form of a public l |
|
| November 8, 2024 |
As filed with the Securities and Exchange Commission on November 8, 2024 As filed with the Securities and Exchange Commission on November 8, 2024 Registration No. |
|
| November 8, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Nyxoah SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Ordinary Shares, no nominal value per share Other 1,000,000 $ 9. |
|
| November 8, 2024 |
Exhibit 99.1 English translation – for information purposes only NYXOAH SA Rue Edouard Belin 12 B-1435 Mont-Saint-Guibert VAT: BE 0817.149.675 Register of legal entities of Walloon Brabant (hereinafter the "Company") 2024 WARRANTS PLAN 1 DEFINITIONS For the purposes of this Plan, the following terms shall have the following meaning: “Articles of Association” means the articles of association of th |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| November 6, 2024 |
INTERIM FINANCIAL REPORT THIRD QUARTER 2024 Table of contents Exhibit 99.2 INTERIM FINANCIAL REPORT THIRD QUARTER 2024 Table of contents Table of contents 1 Interim Financial Report 2 Third Quarter 2024 2 1. Business update 2 2. FINANCIAL HIGHLIGHTS 3 3. 2024 OUTLOOK 4 4. RISK FACTORS 4 5. FORWARD-LOOKING STATEMENTS 4 Unaudited condensed consolidated interim financial information as at and for the nine months ended September 30, 2024 – Interim consolidated s |
|
| November 6, 2024 |
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Third Quarter Financial and Operating Results FDA approval on track for first quarter 2025, U.S. commercial team build out in progress Company fully funded with cash until mid 2026 Mont-Saint-Guibert, Belgium – November 6, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology co |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| November 5, 2024 |
Exhibit 99.1 Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (O |
|
| October 28, 2024 |
Publication relating to transparency notifications Exhibit 99.1 REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 25, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Vestal Point Capital On |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive o |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive o |
|
| October 15, 2024 |
Publication relating to transparency notifications Exhibit 99.1 REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 15, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received three transparency notifications as detailed below. Jürgen Hambrecht On |
|
| October 10, 2024 |
NYXH / Nyxoah S.A. / Cochlear Ltd - SCHEDULE 13D/A Activist Investment SC 13D/A 1 tm2425979d1sc13da.htm SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) Nyxoah SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B6S7WD1 |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive o |
|
| October 9, 2024 |
Information on the total number of voting rights and shares Exhibit 99.2 REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), October 9, 2024, 10:35 pm CET / 4:35 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. · Share capital: EU |
|
| October 9, 2024 |
Publication relating to transparency notifications Exhibit 99.1 REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 9, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On Octobe |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive o |
|
| October 7, 2024 |
Exhibit 99.1 INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $27 Million through its At-the-Market Offering Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus Mont-Saint-Guibert, Belgium – October 7, 2024, 11:00pm CET / 5:00pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| September 30, 2024 |
Publication relating to transparency notifications Exhibit 99.1 Publication relating to transparency notifications September 27, 2024 REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 27, 2024, 8.00am CET / 2.00am ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a |
|
| September 30, 2024 |
Information on the total number of voting rights and shares Exhibit 99.2 Information on the total number of voting rights and shares September 27, 2024 REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), September 27, 2024, 08:05 am CET / 2:05 am ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publ |
|
| September 30, 2024 |
Exhibit 99.3 DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update Additional clinical data on patients suffering from Obstructive Sleep Apnea (OSA) demonstrate a clinically significant 71.0% median reduction in Apnea-Hypopnea index (AHI) while sleeping supine at 12 months compared with baseline. 82.0% of patients who completed a polysomnography at |
|
| August 6, 2024 |
INTERIM FINANCIAL REPORT FIRST HALF 2024 TABLE OF CONTENTS Table of Contents Exhibit 99.2 INTERIM FINANCIAL REPORT FIRST HALF 2024 TABLE OF CONTENTS Table of contents 1 Interim financial report 2 First half 2024 2 1. BUSINESS UPDATE 2 2. FINANCIAL HIGHLIGHTS 4 3. 2024 OUTLOOK 4 4. RISK FACTORS 4 5. FORWARD-LOOKING STATEMENTS 5 Unaudited condensed consolidated interim financial information as at and for the six months ended June 30, 2024 – Interim consolid |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive of |
|
| August 6, 2024 |
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results FDA regulatory submission complete, U.S. approval on track for end of 2024 U.S. commercial launch fully funded with over €85 million in new capital raised Mont-Saint-Guibert, Belgium – August 6, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or t |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| July 17, 2024 |
Nyxoah Appoints Scott Holstine as Chief Commercial Officer Exhibit 99.1 Nyxoah Appoints Scott Holstine as Chief Commercial Officer July 15, 2024 Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Ob |
|
| July 5, 2024 |
Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Exhibit 99.1 REGULATED INFORMATION INSIDE INFORMATION Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat O |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| July 1, 2024 |
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Exhibit 99.1 Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA July 1, 2024 Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024, 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat O |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| July 1, 2024 |
Information on the total number of voting rights and shares Exhibit 99.1 REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. · Share capital: EUR |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| June 3, 2024 |
Publication relating to transparency notifications Exhibit 99.1 REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 3, 2024, 10.05pm CET / 4.05pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received four transparency notifications as detailed below. FMR LLC On May 30, 2024, N |
|
| June 3, 2024 |
Information on the total number of voting rights and shares Exhibit 99.2 REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 3, 2024, 10:15 pm CET / 4:15 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. · Share capital: EUR 5 |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 31, 2024 |
Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares Exhibit 99.1 Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares May 31, 2024 INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares Mont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Nyxoah” or the “Compan |
|
| May 30, 2024 |
NYXH / Nyxoah S.A. / Cochlear Ltd - SC 13D/A Activist Investment SC 13D/A 1 tm2415703d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) Nyxoah SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B6S7WD106 (CU |
|
| May 29, 2024 |
Information on the Total Number of Voting Rights and Shares Exhibit 99.1 Information on the Total Number of Voting Rights and Shares May 28, 2024 REGULATED INFORMATION Information on the Total Number of Voting Rights and Shares Mont-Saint-Guibert (Belgium), May 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the be |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 24, 2024 |
5,374,755 Shares1 Nyxoah SA Ordinary Shares UNDERWRITING AGREEMENT Exhibit 1.1 5,374,755 Shares1 Nyxoah SA Ordinary Shares UNDERWRITING AGREEMENT May 23, 2024 CANTOR FITZGERALD & CO. 110 East 59th Street, 6th Floor New York, NY 10022 As Representative of the several Underwriters named in Schedule I hereto Ladies and Gentlemen: Nyxoah SA, a limited liability company (naamloze vennootschap/société anonyme) organized under the laws of Belgium (the “Company”), p |
|
| May 24, 2024 |
Nyxoah Announces Pricing of Offering Exhibit 99.1 REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Pricing of Offering Mont-Saint-Guibert, Belgium – May 23, 2024, 3:50 pm CET / 9:50 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today the pric |
|
| May 24, 2024 |
Nyxoah SA 5,374,755 Ordinary Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-268955 PROSPECTUS SUPPLEMENT (To prospectus dated January 6, 2023) Nyxoah SA 5,374,755 Ordinary Shares We are offering 5,374,755 of our ordinary shares pursuant to this prospectus supplement. Our ordinary shares are listed on The Nasdaq Global Market under the symbol “NYXH” and on Euronext Brussels under the symbol “NYXH”. O |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 22, 2024 |
Exhibit 99.1 REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium – May 22, 2024, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solut |
|
| May 22, 2024 |
SUBJECT TO COMPLETION, DATED MAY 22, 2024 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| May 14, 2024 |
Exhibit 99.2 Table of contents Table of contents 1 Interim financial report 2 First quarter 2024 2 1. Business update 2 2. FINANCIAL HIGHLIGHTS 3 3. 2024 OUTLOOK 4 4. RISK FACTORS 4 5. FORWARD-LOOKING STATEMENTS 4 Unaudited condensed consolidated interim financial information as at and for the three months ended March 31, 2024 – Interim consolidated statement of financial position 5 Unaudited cond |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 14, 2024 |
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports First Quarter 2024 Financial and Operating Results Announced DREAM U.S. pivotal study achieved primary endpoints On track for FDA approval as early as end of 2024 Mont-Saint-Guibert, Belgium – May 14, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the de |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| April 15, 2024 |
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Exhibit 99.1 Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer April 11, 2024 Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative soluti |
|
| March 20, 2024 |
Table of Contents As filed with the Securities and Exchange Commission on March 20, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 20, 2024 |
Exhibit 1.1 English translation, for information purposes only NYXOAH SA Rue Edouard Belin 12 B-1435 Mont-Saint-Guibert Register of legal entities of Walloon Brabant VAT: BE 0817.149.675 CONSOLIDATED VERSION OF THE ARTICLES OF ASSOCIATION AS PER MARCH 6, 2024 TITLE I. LEGAL FORM, NAME, REGISTERED OFFICE, OBJECT AND DURATION Article 1LEGAL FORM - NAME The company has the legal form of a public limi |
|
| March 20, 2024 |
CERTIFICATIONS UNDER SECTION 302 Exhibit 12.1 CERTIFICATIONS UNDER SECTION 302 I, Olivier Taelman, certify that: 1. I have reviewed this annual report on Form 20-F of Nyxoah SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| March 20, 2024 |
Exhibit 4.11 (English translation for informational purposes only) Attachment to Rental Agreement Drafted and signed in Tel Aviv on November 15, 2023 Between: Gush 7093 Parcel 162 Ltd. Tax ID 510583156 126 Yigal Alon Street, Tel Aviv Hereinafter: “the Lessor” on the one side And: Nyxoah Ltd. Tax ID 514082726 126 Yigal Alon Street, Tel Aviv Hereinafter: “the Lessee” on the other side Whereas the Le |
|
| March 20, 2024 |
Exhibit 4.12 (English Translation for informational purposes only) Attachment to Rental Agreement Drafted and signed in Tel Aviv on November 30, 2023 Between: Gush 7093 Parcel 162 Ltd. Tax ID 510583156 126 Yigal Alon Street, Tel Aviv Hereinafter: “the Lessor” on the one side And: Nyxoah Ltd. Tax ID 514082726 126 Yigal Alon Street, Tel Aviv Hereinafter: “the Lessee” on the other side Whereas the Le |
|
| March 20, 2024 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Nyxoah SA, a Belgian public limited liability company (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December |
|
| March 20, 2024 |
Exhibit 2.2 Description of Securities The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934 of Nyxoah S.A. (“Nyxoah,” “us,” “our,” “we” or the “Company”) is a summary of the rights of our ordinary shares and certain provisions of our articles of association in effect as of March 20, 2024. This summary does not purport to be complete and is q |
|
| March 20, 2024 |
Exhibit 97.1 NYXOAH SA CLAWBACK POLICY I.Introduction The Board of Directors (the “Board”) of Nyxoah SA (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. Notwithstanding the Company’s Remuneration Po |
|
| March 20, 2024 |
CERTIFICATIONS UNDER SECTION 302 Exhibit 12.2 CERTIFICATIONS UNDER SECTION 302 I, Loïc Moreau, certify that: 1. I have reviewed this annual report on Form 20-F of Nyxoah SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res |
|
| March 20, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-3 No 333-268955) of Nyxoah SA, (2) Registration Statement (Form S-8 No. 333-269410) pertaining to the 2022 Warrants Plan of Nyxoah SA, and (3) Registration Statement (Form S-8 No 333-261233) pertaining to the |
|
| March 20, 2024 |
CERTIFICATIONS UNDER SECTION 906 Exhibit 13.2 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Nyxoah SA, a Belgian public limited liability company (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December |
|
| March 19, 2024 |
Exhibit 99.1 REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002) Reports an Oxygen Desaturation Index (ODI) responder rate of 71.3% on an intent to treat (ITT) basis (p<0.001) Median 12-month AHI reduction of 70.8% Mont-Saint-Guibert, Belg |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| March 5, 2024 |
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results Expect to report DREAM U.S. pivotal study efficacy and safety data by early April Achieved record quarterly sales of €1.8 million Mont-Saint-Guibert, Belgium – March 5, 2024 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medic |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| February 14, 2024 |
NYXH / Nyxoah S.A. / TOGETHER PARTNERSHIP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nyxoah SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B6S7WD106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 14, 2024 |
NYXH / Nyxoah S.A. / Taub Robert - SC 13G/A Passive Investment SC 13G/A 1 tm245885d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Nyxoah SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B6S7WD106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| January 17, 2024 |
Nyxoah Announces 2024 Strategic Priorities Exhibit 99.1 Nyxoah Announces 2024 Strategic Priorities Mont-Saint-Guibert, Belgium – January 17, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced, in anticipation of upcoming investor me |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive o |
|
| January 9, 2024 |
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023 Exhibit 99.1 Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023 Mont-Saint-Guibert, Belgium – January 9, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced certa |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive o |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| December 11, 2023 |
Publication Relating to a Transparency Notification Exhibit 99.1 Publication Relating to a Transparency Notification December 8, 2023 REGULATED INFORMATION Publication Relating to a Transparency Notification Mont-Saint-Guibert (Belgium), December 8, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a t |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| November 8, 2023 |
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Third Quarter 2023 Financial and Operating Results Partners with ResMed Germany to increase OSA awareness and therapy penetration Mont-Saint-Guibert, Belgium – November 8, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercializati |
|
| November 8, 2023 |
Interim financial report ThIRD QUARTER 2023 Table of contents Exhibit 99.2 Interim financial report ThIRD QUARTER 2023 Table of contents Table of contents 1 Interim financial report 3 THIRD QUARTER 2023 3 1. Business update 3 2. FINANCIAL HIGHLIGHTS 4 3. 2023 OUTLOOK 5 4. RISK FACTORS 5 5. FORWARD-LOOKING STATEMENTS 5 Unaudited condensed consolidated interim financial information as at and for the nine months ended September 30, 2023 – Interim consolidated s |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| September 29, 2023 |
Exhibit 99.1 Nyxoah Announces Partnership with ResMed in Germany September 28, 2023 Nyxoah Announces Partnership with ResMed in Germany Creates a continuum of care in the German obstructive sleep apnea market Mont-Saint-Guibert, Belgium – September 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the |
|
| August 9, 2023 |
Table of Contents Exhibit 99.2 TABLE OF CONTENTS Table of contents 1 Interim financial report 2 First half 2023 2 1. BUSINESS UPDATE 2 2. FINANCIAL HIGHLIGHTS 3 3. 2023 OUTLOOK 4 4. RISK FACTORS 4 5. FORWARD-LOOKING STATEMENTS 5 Unaudited condensed consolidated interim financial information as at and for the six months ended June 30, 2023 – Interim consolidated statement of financial position 6 Un |
|
| August 9, 2023 |
Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating Results Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating Results Mont-Saint-Guibert, Belgium – August 8, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA) |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive of |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| July 28, 2023 |
Publication relating to a transparency notification Exhibit 99.2 REGULATED INFOMATION Publication relating to a transparency notification Mont-Saint-Guibert (Belgium), July 27, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a rectification of an earlier transparency notification. On July 25, 2023, N |
|
| July 28, 2023 |
Information on the total number of voting rights and shares Exhibit 99.1 REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), July 27, 2023, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. · Share capital: EUR |
|
| July 6, 2023 |
NYXH / Nyxoah SA / RESMED INC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nyxoah SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B6S7WD106 (CUSIP Number) March 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| May 16, 2023 |
Exhibit 99.2 Table of contents Table of contents 1 Interim financial report 3 First quarter 2023 3 1. Business update 3 2. FINANCIAL HIGHLIGHTS 4 3. 2023 OUTLOOK 5 4. RISK FACTORS 5 5. FORWARD-LOOKING STATEMENTS 5 Unaudited condensed consolidated interim financial information as at and for the three months ended March 31, 2023 – Interim consolidated statement of financial position 6 Unaudited cond |
|
| May 16, 2023 |
Nyxoah Reports First Quarter 2023 Financial and Operating Results Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports First Quarter 2023 Financial and Operating Results Mont-Saint-Guibert, Belgium – May 16, 2023 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported f |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 15, 2023 |
Exhibit 99.3 Annual shareholders' meeting of June 14, 2023 / Assemblée générale annuelle des actionnaires du 14 juin 2023 - 1 - NYXOAH SA Rue Edouard Belin 12 1435 Mont-Saint-Guibert Belgium / Belgique VAT / TVA BE 0817.149.675 Register of legal entities Brabant Wallon / Registre des personnes morales du Brabant Wallon FORM FOR VOTING BY MAIL FORMULAIRE DE VOTE PAR CORRESPONDANCE The shareholders |
|
| May 15, 2023 |
Exhibit 99.5 NAME: Legal form: Address: N°. Postal code: Town: Country: Register of legal persons - commercial court: Website : Company registration number 0817.149.675 DATE 10/10/2022 of filing the most recent document mentioning the date of publication of the deed of incorporation and of the deed of amendment of the articles of association. approved by the general meeting of 14/06/2023 regarding |
|
| May 15, 2023 |
Exhibit 99.8 NYXOAH SA REMUNERATION POLICY May 2023 Submitted for approval to the general shareholders’ meeting of Nyxoah SA on June 14, 2023 - 2 - Table of content 1 INTRODUCTION ..................................................................................................................... 3 2 GENERAL PRINCIPLES OF DETERMINATION OF REMUNERATION OF DIRECTORS AND MEMBERS OF EXECUTIVE MANAGEME |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 15, 2023 |
Exhibit 99.9 Annual shareholders' meeting of June 14, 2023 / Assemblée générale annuelle des actionnaires du 14 juin 2023 - 1 - NYXOAH SA Rue Edouard Belin 12 1435 Mont-Saint-Guibert Belgium / Belgique VAT / TVA BE 0817.149.675 Register of legal entities Brabant Wallon / Registre des personnes morales du Brabant Wallon ATTENDANCE NOTIFICATION FORM FOR SECURITIES HOLDERS FORMULAIRE DE NOTIFICATION |
|
| May 15, 2023 |
Exhibit 99.1 REGULATED INFORMATION May 12, 2023, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “Company”) Invitation to attend the annual shareholders’ meeting of the Company to be held on June 14, 2023 The board of directors of the Company is pleased to invite its securities holders to attend the annual sharehold |
|
| May 15, 2023 |
EX-99.4 5 tm2315835d1ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 Annual report 2022 The path to restful nights Annual report 2022 4 Nyxoah SA Annual report 2022 Table of Contents Report of the board of directors to the shareholders for the financial year ending december 31, 2022 1.1 Business overview 14 1.2 Our competitive strengths 17 1.3 Our strategy 19 1.4 Our solution 21 1.4.1 Overview of the Genio s |
|
| May 15, 2023 |
Exhibit 99.7 |
|
| May 15, 2023 |
Exhibit 99.2 Annual shareholders' meeting of June 14, 2023 / Assemblée générale annuelle des actionnaires du 14 juin 2023 - 1 - NYXOAH SA Rue Edouard Belin 12 1435 Mont-Saint-Guibert Belgium / Belgique VAT / TVA BE 0817.149.675 Register of legal entities Brabant Wallon / Registre des personnes morales du Brabant Wallon PROXY FORM FORMULAIRE DE PROCURATION The shareholders that wish to be represent |
|
| May 15, 2023 |
Exhibit 99.6 - 1 - Report of the board of directors to the shareholders’ meeting of Nyxoah SA regarding the statutory annual accounts as of December 31, 2022 Dear Shareholders, We are pleased to present to you our report regarding the financial year which ended on December 31, 2022 and to submit to you for your approval the statutory annual accounts for the financial year which ended on December 3 |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 11, 2023 |
Nyxoah Appoints Christoph Eigenmann as Chief Commercial Officer Exhibit 99.1 Nyxoah Appoints Christoph Eigenmann as Chief Commercial Officer May 10, 2023 Nyxoah Appoints Christoph Eigenmann as Chief Commercial Officer Mont-Saint-Guibert, Belgium – May 10, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to |
|
| April 20, 2023 |
Publication relating to transparency notifications Exhibit 99.1 REGULATED INFOMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), April 20, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below. Together Partnership On Ap |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| April 13, 2023 |
Nyxoah Raises $3 Million from its At-the-Market Equity Offering Exhibit 99.1 INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $3 Million from its At-the-Market Equity Offering Mont-Saint-Guibert, Belgium – April 13, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OS |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| April 6, 2023 |
NYXH / Nyxoah SA / RESMED INC - SC 13G Passive Investment SC 13G CUSIP No. B6S7WD106 13G Page 1 of 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nyxoah SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B6S7WD106 (CUSIP Number) March 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| March 29, 2023 |
NYXH / Nyxoah SA / Cochlear Ltd - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 27, 2023 |
Nyxoah Raises $3 Million from an At-the-Market Equity Offering Exhibit 99.1 Nyxoah Raises $3 Million from an At-the-Market Equity Offering March 27, 2023 INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $3 Million from an At-the-Market Equity Offering Mont-Saint-Guibert, Belgium – March 27, 2023, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and c |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| March 23, 2023 |
Nyxoah Announces a $15 Million Private Placement Financing Exhibit 99.1 INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces a $15 Million Private Placement Financing Mont-Saint-Guibert, Belgium – March 23, 2023, 9:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), to |
|
| March 22, 2023 |
Exhibit 2.2 Description of Securities The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934 of Nyxoah S.A. (“Nyxoah,” “us,” “our,” “we” or the “Company”) is a summary of the rights of our ordinary shares and certain provisions of our articles of association in effect as of March 22, 2023. This summary does not purport to be complete and is q |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| March 22, 2023 |
Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) the Registration Statement (Form F-3 No 333-268955) pertaining to a $200 million shelf offering and $50 million ”at-the-market” offering; (2) the Registration Statement (Form S-8 No. 333-269410) pertaining to the 2022 Warrants Plan; and (3 |
|
| March 22, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on March 22, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 22, 2023 |
Exhibit 12.1 CERTIFICATIONS UNDER SECTION 302 I, Olivier Taelman, certify that: 1. I have reviewed this annual report on Form 20-F of Nyxoah SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| March 22, 2023 |
Exhibit 12.2 CERTIFICATIONS UNDER SECTION 302 I, Loïc Moreau, certify that: 1. I have reviewed this annual report on Form 20-F of Nyxoah SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res |
|
| March 22, 2023 |
Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Nyxoah SA, a Belgian public limited liability company (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December |
|
| March 22, 2023 |
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating Results Completed all 115 implants in the DREAM U.S. pivotal study Mont-Saint-Guibert, Belgium – March 22, 2023 09:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of i |
|
| March 22, 2023 |
Exhibit 13.2 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Nyxoah SA, a Belgian public limited liability company (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| March 6, 2023 |
Exhibit 99.1 Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones March 6, 2023 INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones All 115 patients implanted in DREAM U.S. pivotal study First DREAM PMA module submitted First patient implanted in ACCCESS U.S. pivotal study Mont-Saint-Guibert, Belgium – March 6, 2023, 7:3 |
|
| January 25, 2023 |
Form of 2022 Warrants Plan (English Translation) Exhibit 99.1 English translation – for information purposes only NYXOAH SA Rue Edouard Belin 12 B-1435 Mont-Saint-Guibert VAT: BE 0817.149.675 Register of legal entities of Walloon Brabant (hereinafter the "Company") 2022 WARRANTS PLAN 1 DEFINITIONS For the purposes of this Plan, the following terms shall have the following meaning: “Articles of Association” means the articles of association of th |
|
| January 25, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Nyxoah SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Ordinary Shares, no nominal value per share Other 700,000 $ 5. |
|
| January 25, 2023 |
As filed with the Securities and Exchange Commission on January 25, 2023 As filed with the Securities and Exchange Commission on January 25, 2023 Registration No. |
|
| January 25, 2023 |
Articles of Association, as amended (English Translation) Exhibit 4.1 English translation, for information purposes only NYXOAH SA Rue Edouard Belin 12 B-1435 Mont-Saint-Guibert Register of legal entities of Walloon Brabant VAT: BE 0817.149.675 CONSOLIDATED VERSION OF THE ARTICLES OF ASSOCIATION AS PER SEPTEMBER 30, 2022 TITLE I. Legal form, name, registered office, object and duration Article 1 Legal form - Name The company has the legal form |
|
| January 9, 2023 |
6-K 1 tm232713d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium ( |
|
| January 9, 2023 |
Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors EX-99.1 2 tm232713d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors Mont-Saint-Guibert, Belgium – January 9, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (O |
|
| January 4, 2023 |
Nyxoah SA Rue Edouard Belin 12 1435 Mont-Saint-Guibert, Belgium CORRESP 1 filename1.htm Nyxoah SA Rue Edouard Belin 12 1435 Mont-Saint-Guibert, Belgium January 4, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Benjamin Richie Re: Nyxoah SA Registration Statement on Form F-3 Filed December 22, 2022 File No. 333-268955 Acceleration Request Ladies and Gentlemen: In accord |
|
| January 3, 2023 |
EX-99.1 2 tm231412d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Information on the total number of voting rights and shares December 29, 2022 REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), December 29, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive o |
|
| December 22, 2022 |
Form of Subordinated Indenture EX-4.5 4 tm2232874d2ex4-5.htm EXHIBIT 4.5 Exhibit 4.5 NYXOAH SA Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). |
|
| December 22, 2022 |
Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program Exhibit 99.1 INSIDE INFORMATION REGULATED INFORMATION Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium ? December 22, 2022, 10:10pm CET / 4:10pm ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (?Nyxoah? or the ?Company?), a medical technology company focused on the development and commercialization of innovative solutions to |
|
| December 22, 2022 |
EX-4.4 3 tm2232874d2ex4-4.htm EXHIBIT 4.4 Exhibit 4.4 NYXOAH SA Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act Section of of 1939, as Amended Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a |
|
| December 22, 2022 |
EX-FILING FEES 8 tm2232874d2ex-filingfees.htm EX-FILING FEES EX-FILING FEES Calculation of Filing Fee Tables Form F-3 (Form Type) NYXOAH SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate |
|
| December 22, 2022 |
Form F-3 (Registration Number 333-268955) TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 22, 2022 Registration No. |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| December 22, 2022 |
EX-1.2 2 tm2232874d2ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 Nyxoah SA Ordinary Shares (no par value) Controlled Equity OfferingSM Sales Agreement December 22, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Nyxoah SA, a limited liability company (naamloze vennootschap/société anonyme) organized under the laws of Belgium (the “Company”), confirms its |
|
| November 8, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executiv |
|
| November 8, 2022 |
Table of Contents Exhibit 99.2 TABLE OF CONTENTS ? ? ? Table of contents 1 Interim financial report ? 2 Third quarter 2022 ? 2 1. BUSINESS UPDATE ? 2 2. FINANCIAL HIGHLIGHTS ? 3 3. 2022 OUTLOOK ? 4 4. RISK FACTORS ? 4 5. FORWARD-LOOKING STATEMENTS ? 5 Unaudited condensed consolidated interim financial information as at and for the nine months ended September 30, 2022 ? Interim consolidated stateme |
|
| November 8, 2022 |
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Third Quarter 2022 Financial and Operating Results ? DREAM US pivotal 12-month clinical data expected in fall of 2023 ? Mont-Saint-Guibert, Belgium ? November 8, 2022, 10:05pm CET / 4:05pm ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (?Nyxoah? or the ?Company?), a medical technology company focused on the development and commercialization of inn |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive o |
|
| October 24, 2022 |
Nyxoah announces Change to Board of Directors Exhibit 99.1 Nyxoah announces Change to Board of Directors Mont-Saint-Guibert, Belgium ? October 24, 2022, 10:30pm CET / 4:30pm ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (?Nyxoah? or the ?Company?), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Raymond Cohen resigned as member |
|
| October 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive o |
|
| October 19, 2022 |
Nyxoah to Release Third Quarter Financial Results on November 8, 2022 Exhibit 99.1 Nyxoah to Release Third Quarter Financial Results on November 8, 2022 October 18, 2022 Nyxoah to Release Third Quarter Financial Results on November 8, 2022 Mont-Saint-Guibert, Belgium ? October 18, 2022, 10:30pm CET / 4:30pm ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (?Nyxoah? or the ?Company?), a medical technology company focused on the development and commercialization of inn |
|
| October 3, 2022 |
Exhibit 99.1 Information on the total number of voting rights and shares September 30, 2022 REGULATED INFORMATION Mont-Saint-Guibert (Belgium), September 30, 2022, 10:30 pm CET / 4:30 pm ET ? In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the issue of new shares |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive o |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive of |
|
| August 8, 2022 |
INTERIM FINANCIAL REPORT FIRST HALF 2022 Table of contents Exhibit 99.2 INTERIM FINANCIAL REPORT FIRST HALF 2022 Table of contents Table of contents 1 Interim FINANCIAL report 2 First half 2022 2 1. ?Business update 2 2. ?FINANCIAL HIGHLIGHTS 3 3. ?2022 OUTLOOK 4 4. ?RISK FACTORS 4 5. ? FORWARD-LOOKING STATEMENTS 4 Unaudited condensed consolidated interim financial information as at and for the six months ended June 30, 2022 ? Interim consolidated stateme |
|
| August 8, 2022 |
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results DREAM enrollment complete, 12-month clinical data expected in fall of 2023 Mont-Saint-Guibert, Belgium ? August 8, 2022, 10:05pm CET / 4:05pm ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (?Nyxoah? or the ?Company?), a medical technology company focused on the development and comm |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant’s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive of |
|
| August 2, 2022 |
Exhibit 99.1 Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test August 2, 2022 Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test Mont-Saint-Guibert, Belgium – August 2, 2022, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technolog |
|
| July 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| July 20, 2022 |
Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022 Exhibit 99.1 Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022 July 19, 2022 Nyxoah to Release Second Quarter and First Half 2022 Financial Results on August 8, 2022 Mont-Saint-Guibert, Belgium ? July 19, 2022, 10:30pm CET / 4:30pm ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (?Nyxoah? or the ?Company?), a medical technology company focused on the developm |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| July 19, 2022 |
Exhibit 99.1 Nyxoah Announces CE Mark Approval for Genio? 2.1 July 18, 2022 Nyxoah Announces CE Mark Approval for Genio? 2.1 The next generation external activation chip leverages Nyxoah?s scalable platform to continuously enhance patient comfort and therapy efficacy Mont-Saint-Guibert, Belgium ? July 18, 2022, 10:30pm CET / 4:30pm ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(?Nyxoah? or the ?C |
|
| July 11, 2022 |
Exhibit 99.1 Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio? in Complete Concentric Collapse Patients July 11, 2022 REGULATED INFORMATION INSIDE INFORMATION Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio? in Complete Concentric Collapse Patients First ACCCESS patient expected to be implanted in Q4 2022 Mont-Saint-Guibert, Belgium ? July 11, 2022, 8 |
|
| July 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| July 1, 2022 |
Exhibit 99.1 Information on the total number of voting rights and shares June 30, 2022 REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 30, 2022, 10:30 pm CET / 4:30 pm ET ? In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offi |
|
| June 2, 2022 |
Exhibit 99.1 FDA Approves Genio? 2.1 For Use in DREAM U.S. IDE Pivotal Study New smartphone application, upgraded activation chip, improved user interface, and stimulation amplitude trimming enhance patient experience and comfort Mont-Saint-Guibert, Belgium ? June 1, 2022, 10:30pm CET / 4:30pm ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (?Nyxoah? or the ?Company?), a medical technology company |
|
| May 10, 2022 |
Nyxoah Reports First Quarter 2022 Financial and Operating Results Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports First Quarter 2022 Financial and Operating Results Mont-Saint-Guibert, Belgium ? May 10, 2022, 08:50pm CET / 2:50pm ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (?Nyxoah? or the ?Company?), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 9, 2022 |
Nyxoah Reports First Quarter 2022 Financial and Operating Results Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports First Quarter 2022 Financial and Operating Results Mont-Saint-Guibert, Belgium ? May 9, 2022, 10:30pm CET / 4:30pm ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (?Nyxoah? or the ?Company?), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported f |
|
| May 6, 2022 |
Nyxoah Nominates Raymond Cohen and Virginia Kirby for Appointment to Its Board of Directors Exhibit 99.2 Nyxoah Nominates Raymond Cohen and Virginia Kirby for Appointment to Its Board of Directors Mont-Saint-Guibert, Belgium ? May 6, 2022, 7:00am CET / 1:00am ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (?Nyxoah? or the ?Company?), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announc |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive offic |
|
| May 6, 2022 |
EX-99.1 2 tm2214636d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 REGULATED INFORMATION May 6, 2022, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “Company”) Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 8, 2022 The board of directors of the Company is pleas |
|
| March 24, 2022 |
Exhibit 2.2 Description of Securities The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934 of Nyxoah S.A. (?Nyxoah,? ?us,? ?our,? ?we? or the ?Company?) is a summary of the rights of our ordinary shares and certain provisions of our articles of association in effect as of March 24, 2022. This summary does not purport to be complete and is q |
|
| March 24, 2022 |
Exhibit 12.1 CERTIFICATIONS UNDER SECTION 302 I, Olivier Taelman, certify that: 1. I have reviewed this annual report on Form 20-F of Nyxoah SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with |
|
| March 24, 2022 |
Exhibit 13.2 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Nyxoah SA, a Belgian public limited liability company (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT |
|
| March 24, 2022 |
Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-261233) pertaining to the 2013 Share Incentive Plan, 2016 Warrants Plan, 2018 Warrants Plan, 2020 Warrants Plan, 2021 Warrants Plan, of our report dated March 25, 2022, with respect to the consolidated financial statements of Nyxoah SA i |
|
| March 24, 2022 |
Nyxoah Reports Full Year 2021 Operating and Financial Results Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Full Year 2021 Operating and Financial Results Mont-Saint-Guibert, Belgium ? March 24, 2022, 9:30pm CET / 4:30pm ET ? Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (?Nyxoah? or the ?Company?), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported fin |
|
| March 24, 2022 |
Exhibit 13.1 CERTIFICATIONS UNDER SECTION 906 Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Nyxoah SA, a Belgian public limited liability company (the “Company”), does hereby certify, to such officer’s knowledge, that: The Annual Report for the year ended December |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| March 24, 2022 |
Exhibit 12.2 CERTIFICATIONS UNDER SECTION 302 I, Loïc Moreau, certify that: 1. I have reviewed this annual report on Form 20-F of Nyxoah SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with res |
|
| March 17, 2022 |
BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts Exhibit 99.1 BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts March 14, 2022 BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts ? First clinical data demonstrating effectiveness of HGNS to treat CCC patients ? As previously disclosed, confirms achievement of primary endpoint of AHI4 reductions for entire population, CCC cohort, and non-CCC cohort at six months, and |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive off |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-40552 NYXOAH SA (Translation of registrant?s name into English) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (Address of principal executive |
|
| February 14, 2022 |
NYXH / Nyxoah SA / TOGETHER PARTNERSHIP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nyxoah SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B6S7WD106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 14, 2022 |
Information on the total number of voting rights and shares Exhibit 99.1 Information on the total number of voting rights and shares February 11, 2022 REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 11, 2022, 10:30 pm CET / 4:30 pm ET ? In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publis |
|
| February 11, 2022 |
NYXH / Nyxoah SA / Taub Robert - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nyxoah SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B6S7WD106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 10, 2022 |
NYXH / Nyxoah SA / Gilde Healthcare Holding B.V. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nyxoah SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B6S7WD106 (CUSIP number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Rule |
|
| February 10, 2022 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) Exhibit 99.1 Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The und |
